Incyte Corporation (0J9P.L)
USD 62.01
(1.56%)
USD 62.01
(1.56%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.69 Billion USD | 8.87% |
| 2022 | 3.39 Billion USD | 13.67% |
| 2021 | 2.98 Billion USD | 11.98% |
| 2020 | 2.66 Billion USD | 23.53% |
| 2019 | 2.15 Billion USD | 14.71% |
| 2018 | 1.88 Billion USD | 22.5% |
| 2017 | 1.53 Billion USD | 38.93% |
| 2016 | 1.1 Billion USD | 46.7% |
| 2015 | 753.75 Million USD | 47.36% |
| 2014 | 511.49 Million USD | 44.1% |
| 2013 | 354.94 Million USD | 19.49% |
| 2012 | 297.05 Million USD | 214.5% |
| 2011 | 94.45 Million USD | -44.4% |
| 2010 | 169.87 Million USD | 1733.55% |
| 2009 | 9.26 Million USD | 136.41% |
| 2008 | 3.91 Million USD | -88.62% |
| 2007 | 34.44 Million USD | 24.59% |
| 2006 | 27.64 Million USD | 252.32% |
| 2005 | 7.84 Million USD | -44.54% |
| 2004 | 14.14 Million USD | -69.96% |
| 2003 | 47.09 Million USD | -53.66% |
| 2002 | 101.61 Million USD | -53.66% |
| 2001 | 219.26 Million USD | 12.92% |
| 2000 | 194.16 Million USD | 23.67% |
| 1999 | 157 Million USD | 16.47% |
| 1998 | 134.8 Million USD | 52.49% |
| 1997 | 88.4 Million USD | 111.48% |
| 1996 | 41.8 Million USD | 242.62% |
| 1995 | 12.2 Million USD | 6000.0% |
| 1994 | 200 Thousand USD | -33.33% |
| 1993 | 300 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 1.13 Billion USD | 9.02% |
| 2024 Q1 | 880.88 Million USD | -13.07% |
| 2024 Q2 | 1.04 Billion USD | 18.49% |
| 2023 Q3 | 919.02 Million USD | -3.73% |
| 2023 FY | 3.69 Billion USD | 8.87% |
| 2023 Q4 | 1.01 Billion USD | 10.26% |
| 2023 Q1 | 808.67 Million USD | -12.74% |
| 2023 Q2 | 954.61 Million USD | 18.05% |
| 2022 Q1 | 733.23 Million USD | -15.02% |
| 2022 FY | 3.39 Billion USD | 13.67% |
| 2022 Q4 | 926.7 Million USD | 12.56% |
| 2022 Q3 | 823.3 Million USD | -9.67% |
| 2022 Q2 | 911.39 Million USD | 24.3% |
| 2021 Q2 | 705.7 Million USD | 16.7% |
| 2021 Q3 | 812.98 Million USD | 15.2% |
| 2021 Q4 | 862.85 Million USD | 6.13% |
| 2021 FY | 2.98 Billion USD | 11.98% |
| 2021 Q1 | 604.71 Million USD | -23.41% |
| 2020 Q3 | 620.64 Million USD | -9.8% |
| 2020 Q1 | 568.5 Million USD | -1.88% |
| 2020 Q2 | 688.04 Million USD | 21.03% |
| 2020 FY | 2.66 Billion USD | 23.53% |
| 2020 Q4 | 789.5 Million USD | 27.21% |
| 2019 Q2 | 529.93 Million USD | 6.44% |
| 2019 Q1 | 497.85 Million USD | -5.78% |
| 2019 FY | 2.15 Billion USD | 14.71% |
| 2019 Q3 | 551.58 Million USD | 4.09% |
| 2019 Q4 | 579.38 Million USD | 5.04% |
| 2018 Q3 | 449.68 Million USD | -13.77% |
| 2018 Q4 | 528.4 Million USD | 17.51% |
| 2018 Q1 | 382.28 Million USD | -13.93% |
| 2018 FY | 1.88 Billion USD | 22.5% |
| 2018 Q2 | 521.51 Million USD | 36.42% |
| 2017 Q2 | 326.44 Million USD | -15.01% |
| 2017 FY | 1.53 Billion USD | 38.93% |
| 2017 Q1 | 384.08 Million USD | 17.64% |
| 2017 Q3 | 381.53 Million USD | 16.88% |
| 2017 Q4 | 444.15 Million USD | 16.41% |
| 2016 Q3 | 269.46 Million USD | 9.41% |
| 2016 Q2 | 246.28 Million USD | -6.52% |
| 2016 FY | 1.1 Billion USD | 46.7% |
| 2016 Q1 | 263.46 Million USD | 8.03% |
| 2016 Q4 | 326.49 Million USD | 21.16% |
| 2015 Q4 | 243.88 Million USD | 29.99% |
| 2015 Q2 | 162.98 Million USD | 2.33% |
| 2015 FY | 753.75 Million USD | 47.36% |
| 2015 Q3 | 187.61 Million USD | 15.11% |
| 2015 Q1 | 159.27 Million USD | 28.48% |
| 2014 Q1 | 89.79 Million USD | -7.5% |
| 2014 Q3 | 198.14 Million USD | 98.98% |
| 2014 Q2 | 99.58 Million USD | 10.9% |
| 2014 Q4 | 123.97 Million USD | -37.43% |
| 2014 FY | 511.49 Million USD | 44.1% |
| 2013 Q4 | 97.07 Million USD | 14.04% |
| 2013 Q2 | 101.67 Million USD | 43.05% |
| 2013 Q1 | 71.07 Million USD | -37.57% |
| 2013 FY | 354.94 Million USD | 19.49% |
| 2013 Q3 | 85.12 Million USD | -16.28% |
| 2012 Q2 | 86.54 Million USD | 139.21% |
| 2012 Q4 | 113.84 Million USD | 88.2% |
| 2012 Q3 | 60.49 Million USD | -30.1% |
| 2012 Q1 | 36.17 Million USD | 25.23% |
| 2012 FY | 297.05 Million USD | 214.5% |
| 2011 Q1 | 31.97 Million USD | -62.77% |
| 2011 FY | 94.45 Million USD | -44.4% |
| 2011 Q4 | 28.89 Million USD | 72.15% |
| 2011 Q3 | 16.78 Million USD | -0.17% |
| 2011 Q2 | 16.81 Million USD | -47.42% |
| 2010 FY | 169.87 Million USD | 1733.55% |
| 2010 Q4 | 85.87 Million USD | 408.95% |
| 2010 Q3 | 16.87 Million USD | -66.15% |
| 2010 Q2 | 49.84 Million USD | 188.33% |
| 2010 Q1 | 17.28 Million USD | 151.79% |
| 2009 Q4 | 6.86 Million USD | 631.2% |
| 2009 FY | 9.26 Million USD | 136.41% |
| 2009 Q1 | 671 Thousand USD | -28.46% |
| 2009 Q2 | 789 Thousand USD | 17.59% |
| 2009 Q3 | 939 Thousand USD | 19.01% |
| 2008 Q1 | 1.3 Million USD | -86.6% |
| 2008 Q4 | 938 Thousand USD | -11.59% |
| 2008 FY | 3.91 Million USD | -88.62% |
| 2008 Q2 | 614 Thousand USD | -53.02% |
| 2008 Q3 | 1.06 Million USD | 72.8% |
| 2007 Q1 | 7.42 Million USD | 5.19% |
| 2007 Q2 | 10.57 Million USD | 42.5% |
| 2007 Q3 | 6.69 Million USD | -36.74% |
| 2007 Q4 | 9.75 Million USD | 45.77% |
| 2007 FY | 34.44 Million USD | 24.59% |
| 2006 Q2 | 6.85 Million USD | 6.03% |
| 2006 Q4 | 7.05 Million USD | -2.92% |
| 2006 Q3 | 7.26 Million USD | 6.02% |
| 2006 Q1 | 6.46 Million USD | 528.89% |
| 2006 FY | 27.64 Million USD | 252.32% |
| 2005 Q1 | 2.91 Million USD | 377.09% |
| 2005 Q4 | 1.02 Million USD | -16.29% |
| 2005 Q2 | 2.67 Million USD | -8.2% |
| 2005 Q3 | 1.22 Million USD | -54.11% |
| 2005 FY | 7.84 Million USD | -44.54% |
| 2004 FY | 14.14 Million USD | -69.96% |
| 2004 Q1 | 6.64 Million USD | -35.51% |
| 2004 Q2 | 5.16 Million USD | -22.26% |
| 2004 Q3 | 3.39 Million USD | -34.28% |
| 2004 Q4 | -1.05 Million USD | -131.01% |
| 2003 Q2 | 11.03 Million USD | -11.78% |
| 2003 Q4 | 10.29 Million USD | -22.27% |
| 2003 Q3 | 13.24 Million USD | 20.05% |
| 2003 Q1 | 12.5 Million USD | -40.85% |
| 2003 FY | 47.09 Million USD | -53.66% |
| 2002 Q4 | 21.14 Million USD | -5.54% |
| 2002 Q2 | 29.05 Million USD | 0.16% |
| 2002 FY | 101.61 Million USD | -53.66% |
| 2002 Q3 | 22.39 Million USD | -22.95% |
| 2002 Q1 | 29.01 Million USD | -47.03% |
| 2001 Q3 | 57.31 Million USD | 2.26% |
| 2001 Q2 | 56.05 Million USD | 9.64% |
| 2001 FY | 219.26 Million USD | 12.92% |
| 2001 Q4 | 54.77 Million USD | -4.44% |
| 2001 Q1 | 51.12 Million USD | -7.75% |
| 2000 Q3 | 51.98 Million USD | 12.97% |
| 2000 Q2 | 46.01 Million USD | 12.91% |
| 2000 FY | 194.16 Million USD | 23.67% |
| 2000 Q1 | 40.75 Million USD | -11.6% |
| 2000 Q4 | 55.41 Million USD | 6.61% |
| 1999 Q2 | 37.9 Million USD | 0.8% |
| 1999 Q3 | 35.4 Million USD | -6.6% |
| 1999 Q4 | 46.1 Million USD | 30.23% |
| 1999 Q1 | 37.6 Million USD | 2.73% |
| 1999 FY | 157 Million USD | 16.47% |
| 1998 Q4 | 36.6 Million USD | 5.48% |
| 1998 Q2 | 33.1 Million USD | 8.88% |
| 1998 FY | 134.8 Million USD | 52.49% |
| 1998 Q1 | 30.4 Million USD | 13.86% |
| 1998 Q3 | 34.7 Million USD | 4.83% |
| 1997 Q3 | 22.7 Million USD | 7.08% |
| 1997 FY | 88.4 Million USD | 111.48% |
| 1997 Q4 | 26.7 Million USD | 17.62% |
| 1997 Q1 | 17.9 Million USD | 26.06% |
| 1997 Q2 | 21.2 Million USD | 18.44% |
| 1996 Q1 | 5.6 Million USD | 14.29% |
| 1996 Q3 | 12.9 Million USD | 69.74% |
| 1996 FY | 41.8 Million USD | 242.62% |
| 1996 Q4 | 14.2 Million USD | 10.08% |
| 1996 Q2 | 7.6 Million USD | 35.71% |
| 1995 Q3 | 2.9 Million USD | 45.0% |
| 1995 Q2 | 2 Million USD | 33.33% |
| 1995 Q4 | 4.9 Million USD | 68.97% |
| 1995 Q1 | 1.5 Million USD | 1400.0% |
| 1995 FY | 12.2 Million USD | 6000.0% |
| 1994 Q1 | 100 Thousand USD | 0.0% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| 1994 FY | 200 Thousand USD | -33.33% |
| 1994 Q4 | 100 Thousand USD | 0.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1993 FY | 300 Thousand USD | 0.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 Q4 | - USD | -100.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| uniQure N.V. | 15.84 Million USD | -23226.699% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -105489.971% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -11726.455% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -13677.911% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -43008.002% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -17525.186% |
| Imunon, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 232.28 Million USD | -1491.005% |
| Editas Medicine, Inc. | 78.12 Million USD | -4630.552% |
| FibroGen, Inc. | 147.75 Million USD | -2401.251% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -310719.933% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | -95.837% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -197.237% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -508.316% |
| Verastem, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 8.54 Billion USD | 56.746% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 62.554% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -1997.036% |
| Homology Medicines, Inc. | -6.65 Million USD | 55665.313% |
| Nektar Therapeutics | 90.12 Million USD | -4000.718% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | 20.619% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -3076.757% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 97.497% |
| Illumina, Inc. | 4.5 Billion USD | 17.947% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 91.377% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 75.336% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -2808.952% |
| Waters Corporation | 2.95 Billion USD | -25.004% |
| Biogen Inc. | 9.83 Billion USD | 62.426% |
| Evolus, Inc. | 202.08 Million USD | -1728.76% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| bluebird bio, Inc. | 29.49 Million USD | -12428.898% |
| Geron Corporation | 237 Thousand USD | -1559245.57% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -102.137% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -825.402% |
| Myriad Genetics, Inc. | 678.4 Million USD | -444.76% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -10087.868% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 2.446% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | -52.762% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 71.826% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 45.915% |
| OPKO Health, Inc. | 863.49 Million USD | -327.987% |
| Exelixis, Inc. | 1.83 Billion USD | -101.925% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -666.136% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -1265.724% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -369.201% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -345.66% |
| Blueprint Medicines Corporation | 249.38 Million USD | -1381.935% |
| Insmed Incorporated | 305.2 Million USD | -1110.862% |
| TG Therapeutics, Inc. | 233.66 Million USD | -1481.622% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -252.201% |